3-rx.comCustomer Support
3-rx.com
   
HomeAbout UsFAQContactHelp
News Center
Health Centers
Medical Encyclopedia
Drugs & Medications
Diseases & Conditions
Medical Symptoms
Med. Tests & Exams
Surgery & Procedures
Injuries & Wounds
Diet & Nutrition
Special Topics



\"$alt_text\"');"); } else { echo"\"$alt_text\""; } ?>


Join our Mailing List





Syndicate

You are here : 3-RX.com > Home > Cancer -

Blocking stomach acid doesn’t raise cancer risk

CancerNov 02, 06

Overall, the use of drugs that reduce stomach acid, such as H2 blockers and proton pump inhibitors, do not increase the risk of cancer of the esophagus or stomach, according to a study reported in the journal Gut.

Common H2 blockers are ranitidine (Zantac) and cimetidine (Tagamet); and a common proton pump inhibitor is omeprazole (Prilosec).

“There have been concerns regarding the safety of long-time gastric acid suppression,” senior investigator Dr. Mats Lindblad told Reuters Health. “I think our large study clearly suggests that long-time gastric acid suppression does not increase the risk” of cancer of the esophagus or stomach.

Lindblad and colleagues at the Karolinska Institute in Stockholm evaluated 7 years of patient data entered into the UK general practice database. The team identified 287 patients with esophageal cancer and 522 with stomach cancer. These subjects were compared with 10,000 randomly selected subjects without cancer.

The authors found some conditions for which acid-suppressing drugs are used, such as acid reflux disease, hiatal hernia and Barrett’s esophagus, were associated with an increased risk of stomach and esophagus cancer. However, no apparent cancer risk was seen with other conditions, including peptic ulcer, gastritis, and indigestion. They found no evidence that the drugs themselves increased the risk.

These findings are in line with those of previous studies, continued Lindblad. The new information is that the cancer risk is probably due to underlying conditions, rather than an independent, harmful effect of these drugs.

In an interview with Reuters Health, Dr. Kenneth E.L. McColl, author of an accompanying editorial, agreed that the findings are consistent with such a conclusion.

However, McColl of the Western Infirmary, Glasgow, UK added that “a major weakness in the study is the relatively short duration of acid suppressive therapy examined. The development of cancer in humans is a slow process.”

The period in question “is really too short to identify or exclude any direct effect between acid suppressive medication and” stomach or esophageal cancers.

SOURCE: Gut, November 2006.



Print Version
Tell-a-Friend
comments powered by Disqus

RELATED ARTICLES:
  New biomarkers may influence drug design and alternative treatments of cancer, study shows
  Metabolic profiles distinguish early stage ovarian cancer with unprecedented accuracy
  Moffitt researchers develop first genetic test to predict tumor sensitivity to radiation therapy
  New drug for neuroblastoma shows promise in phase I study
  Experimental treatment sends deadly leukemia into remission
  Study could reduce unnecessary cancer screening
  UA researchers discover component of cinnamon prevents colorectal cancer in mice
  Profiling approach to enable right lung cancer treatment match
  Fat grafting technique improves results of breast augmentation
  Germline TP53 mutations in patients with early-onset colorectal cancer
  Clinical trial suggests combination therapy is best for low-grade brain tumors
  UW research shows sensor technology may help improve accuracy of clinical breast exams

 












Home | About Us | FAQ | Contact | Advertising Policy | Privacy Policy | Bookmark Site